JPS6330416A - 脳循環代謝改善剤 - Google Patents
脳循環代謝改善剤Info
- Publication number
- JPS6330416A JPS6330416A JP61174367A JP17436786A JPS6330416A JP S6330416 A JPS6330416 A JP S6330416A JP 61174367 A JP61174367 A JP 61174367A JP 17436786 A JP17436786 A JP 17436786A JP S6330416 A JPS6330416 A JP S6330416A
- Authority
- JP
- Japan
- Prior art keywords
- bis
- phenyl
- dioxabicyclo
- agent
- metabolism
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000002490 cerebral effect Effects 0.000 title claims abstract description 19
- 230000004087 circulation Effects 0.000 title claims description 13
- 230000004060 metabolic process Effects 0.000 title claims description 13
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 10
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract 4
- 125000000188 beta-D-glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 2
- 239000004480 active ingredient Substances 0.000 claims description 5
- XNWFXTOHNKPYMK-UHFFFAOYSA-N 3,3a,4,5,6,6a-hexahydrocyclopenta[c]dioxole Chemical class C1OOC2CCCC21 XNWFXTOHNKPYMK-UHFFFAOYSA-N 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 17
- 239000003814 drug Substances 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 6
- -1 piperitol compound Chemical class 0.000 abstract description 3
- 239000011230 binding agent Substances 0.000 abstract description 2
- 239000003085 diluting agent Substances 0.000 abstract description 2
- 201000010099 disease Diseases 0.000 abstract description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 2
- 239000008187 granular material Substances 0.000 abstract description 2
- 239000000546 pharmaceutical excipient Substances 0.000 abstract description 2
- 239000000843 powder Substances 0.000 abstract description 2
- LCDOURUENWKEAD-UHFFFAOYSA-N 3,6-diphenyl-1,3,3a,4,6,6a-hexahydrofuro[3,4-c]furan Chemical class C12COC(C=3C=CC=CC=3)C2COC1C1=CC=CC=C1 LCDOURUENWKEAD-UHFFFAOYSA-N 0.000 abstract 2
- 244000131415 Zanthoxylum piperitum Species 0.000 abstract 2
- 235000008853 Zanthoxylum piperitum Nutrition 0.000 abstract 2
- BURBOJZOZGMMQF-UHFFFAOYSA-N xanthoxylol Natural products C1=C(O)C(OC)=CC=C1C1C(COC2C=3C=C4OCOC4=CC=3)C2CO1 BURBOJZOZGMMQF-UHFFFAOYSA-N 0.000 abstract 2
- HGXBRUKMWQGOIE-AFHBHXEDSA-N (+)-pinoresinol Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@@H]3[C@@H]([C@H](OC3)C=3C=C(OC)C(O)=CC=3)CO2)=C1 HGXBRUKMWQGOIE-AFHBHXEDSA-N 0.000 abstract 1
- 241000208689 Eucommia ulmoides Species 0.000 abstract 1
- 241000576429 Forsythia suspensa Species 0.000 abstract 1
- KFFCKOBAHMGTMW-LGQRSHAYSA-N Forsythin Chemical compound C1=C(OC)C(OC)=CC=C1[C@H]1[C@@H](CO[C@@H]2C=3C=C(OC)C(O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)=CC=3)[C@@H]2CO1 KFFCKOBAHMGTMW-LGQRSHAYSA-N 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- MFIHSKBTNZNJIK-UHFFFAOYSA-N medioresinol dimethyl ether Natural products C1=C(OC)C(OC)=CC=C1C1C(COC2C=3C=C(OC)C(OC)=C(OC)C=3)C2CO1 MFIHSKBTNZNJIK-UHFFFAOYSA-N 0.000 abstract 1
- OHOPKHNWLCMLSW-UHFFFAOYSA-N pinoresinol Natural products C1=C(O)C(OC)=CC(C2C3C(C(OC3)C=3C=C(CO)C(O)=CC=3)CO2)=C1 OHOPKHNWLCMLSW-UHFFFAOYSA-N 0.000 abstract 1
- 235000007221 pinoresinol Nutrition 0.000 abstract 1
- VPSRGTGHZKLTBU-UHFFFAOYSA-N piperitol Natural products COc1ccc(cc1OCC=C(C)C)C2OCC3C2COC3c4ccc5OCOc5c4 VPSRGTGHZKLTBU-UHFFFAOYSA-N 0.000 abstract 1
- HPOHAUWWDDPHRS-UHFFFAOYSA-N trans-piperitol Natural products CC(C)C1CCC(C)=CC1O HPOHAUWWDDPHRS-UHFFFAOYSA-N 0.000 abstract 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical class CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 15
- 210000004556 brain Anatomy 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 210000003743 erythrocyte Anatomy 0.000 description 6
- 206010018910 Haemolysis Diseases 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000008588 hemolysis Effects 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000012085 test solution Substances 0.000 description 4
- 241000700159 Rattus Species 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000037149 energy metabolism Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- LVUPFEOCDSHRBL-UHFFFAOYSA-N syringaresinol Natural products COc1cccc(OC)c1C2OCC3C2COC3c4c(OC)cccc4OC LVUPFEOCDSHRBL-UHFFFAOYSA-N 0.000 description 2
- 229930189508 virginol Natural products 0.000 description 2
- PEYUIKBAABKQKQ-AFHBHXEDSA-N (+)-sesamin Chemical class C1=C2OCOC2=CC([C@H]2OC[C@H]3[C@@H]2CO[C@@H]3C2=CC=C3OCOC3=C2)=C1 PEYUIKBAABKQKQ-AFHBHXEDSA-N 0.000 description 1
- VRYALKFFQXWPIH-PBXRRBTRSA-N (3r,4s,5r)-3,4,5,6-tetrahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)CC=O VRYALKFFQXWPIH-PBXRRBTRSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 241000157282 Aesculus Species 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 235000015701 Artemisia arbuscula Nutrition 0.000 description 1
- 235000002657 Artemisia tridentata Nutrition 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- 240000006891 Artemisia vulgaris Species 0.000 description 1
- 206010008635 Cholestasis Diseases 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000555712 Forsythia Species 0.000 description 1
- 241001198917 Forsythia ovata Species 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 210000002376 aorta thoracic Anatomy 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000007870 cholestasis Effects 0.000 description 1
- 231100000359 cholestasis Toxicity 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000081 effect on glucose Effects 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000010181 horse chestnut Nutrition 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229930013686 lignan Natural products 0.000 description 1
- 150000005692 lignans Chemical class 0.000 description 1
- 235000009408 lignans Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- KOWMJRJXZMEZLD-UHFFFAOYSA-N syringaresinol Chemical compound COC1=C(O)C(OC)=CC(C2C3C(C(OC3)C=3C=C(OC)C(O)=C(OC)C=3)CO2)=C1 KOWMJRJXZMEZLD-UHFFFAOYSA-N 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61174367A JPS6330416A (ja) | 1986-07-24 | 1986-07-24 | 脳循環代謝改善剤 |
| US07/075,963 US4816481A (en) | 1986-07-24 | 1987-07-21 | Method for improving cerebral circulation |
| EP87306482A EP0255287A3 (en) | 1986-07-24 | 1987-07-22 | Cerebral-circulation-metabolism-function-improving agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61174367A JPS6330416A (ja) | 1986-07-24 | 1986-07-24 | 脳循環代謝改善剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS6330416A true JPS6330416A (ja) | 1988-02-09 |
| JPH0560811B2 JPH0560811B2 (enExample) | 1993-09-03 |
Family
ID=15977376
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP61174367A Granted JPS6330416A (ja) | 1986-07-24 | 1986-07-24 | 脳循環代謝改善剤 |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US4816481A (enExample) |
| EP (1) | EP0255287A3 (enExample) |
| JP (1) | JPS6330416A (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003039570A1 (en) * | 2001-11-06 | 2003-05-15 | Sung Jin Kim | Composition containing an extract of pericarpium zanthoxyli for protecting brain cells and improving memory |
| JP2016502539A (ja) * | 2012-11-30 | 2016-01-28 | 株式会社アモーレパシフィックＡｍｏｒｅｐａｃｉｆｉｃ Ｃｏｒｐｏｒａｔｉｏｎ | 心臓疾患の予防又は治療用組成物 |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3070611B2 (ja) * | 1989-03-07 | 2000-07-31 | サントリー株式会社 | △▲上５▼―不飽和化酵素阻害剤 |
| US5562906A (en) * | 1989-09-12 | 1996-10-08 | Terry; James M. | Method for the treatment of vascular disorders |
| AU716372C (en) * | 1995-07-04 | 2001-07-26 | Suntory Holdings Limited | Food composition containing an omega-6/omega-3 unsaturated fatty acid balance modifier |
| WO2003066556A1 (en) * | 2002-02-05 | 2003-08-14 | Hormos Medical Corporation | Lignan derivatives |
| KR101938396B1 (ko) * | 2017-05-15 | 2019-01-15 | 주식회사 파이토코퍼레이션 | 퉁퉁마디 추출물을 포함하는 치매 예방 또는 치료 및 인지기능 개선용 약제학적 조성물 |
| CN113398113A (zh) * | 2021-06-23 | 2021-09-17 | 陕西中医药大学 | 松脂素在制备抑制血栓形成的药物中的用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS52102433A (en) * | 1976-02-19 | 1977-08-27 | Microbial Chem Res Found | Hypotensive agents containing 1,4-dihydroxy-1,4-di-(3,5-dimethoxy-4-hy droxyphenyl)butane-2,3-dicarboxylic acid dilactone as main component |
| US4103006A (en) * | 1976-05-20 | 1978-07-25 | Wisconsin Alumni Research Foundation | Glycosides of 2,6-bis(hydroxy-phenyl)-3,7-dioxabicyclo [3,3,0] octane |
| JPS5473789A (en) * | 1977-11-15 | 1979-06-13 | Microbial Chem Res Found | 2,6-diphenyl-3,7-dioxabicyclo-3.3.0-octane 4,8-dione derivative and anticarcinogens, catechol-o-methyl transferase inhibitors and adenosine 3',5'-cyclic phosphoric acid phosphodiesterase inhibitors containing the derivative as active component |
| JPS61218590A (ja) * | 1985-03-22 | 1986-09-29 | Jujo Paper Co Ltd | ２，６−ビス（４−ヒドロキシ−３，５−ジメトキシフエニル）−３，７−ジオキサビシクロ〔３．３．０〕オクタンの製造法 |
-
1986
- 1986-07-24 JP JP61174367A patent/JPS6330416A/ja active Granted
-
1987
- 1987-07-21 US US07/075,963 patent/US4816481A/en not_active Expired - Fee Related
- 1987-07-22 EP EP87306482A patent/EP0255287A3/en not_active Withdrawn
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003039570A1 (en) * | 2001-11-06 | 2003-05-15 | Sung Jin Kim | Composition containing an extract of pericarpium zanthoxyli for protecting brain cells and improving memory |
| JP2016502539A (ja) * | 2012-11-30 | 2016-01-28 | 株式会社アモーレパシフィックＡｍｏｒｅｐａｃｉｆｉｃ Ｃｏｒｐｏｒａｔｉｏｎ | 心臓疾患の予防又は治療用組成物 |
| US9795583B2 (en) | 2012-11-30 | 2017-10-24 | Amorepacific Corporation | Composition for preventing or treating heart disease |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0560811B2 (enExample) | 1993-09-03 |
| US4816481A (en) | 1989-03-28 |
| EP0255287A3 (en) | 1989-10-18 |
| EP0255287A2 (en) | 1988-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4595693A (en) | Method of use of 2,5-diaryl tetrahydrofurans and analogs thereof as PAF-antagonists | |
| JPS60116679A (ja) | 血小板活性化因子‐拮抗体としての新規２，５‐ジアリールテトラヒドロフラン及びその類縁体 | |
| JPS62230722A (ja) | 肥満および／または関連状態の治療剤 | |
| WO2001003690A1 (en) | Novel vasodilator cannabinoid analogs | |
| DE2160148C2 (de) | Arzneimittel und bestimmte Sulfoxide als solche | |
| US4918099A (en) | Drug, preparation and use thereof | |
| JPS6330416A (ja) | 脳循環代謝改善剤 | |
| NO160206B (no) | Fremgangsmaate ved fremstilling av isosilybinfri silibinin. | |
| Mechoulam | Looking back at Cannabis research | |
| EP0038343B1 (de) | Substituierte oxocarbonsäuren, verfahren zu ihrer herstellung, ihre verwendung und sie enthaltende arzneimittel | |
| EP0157267A2 (de) | Substituierte Benzopyrane, Verfahren zu ihrer Herstellung sowie ihre Verwendung in Arzneimitteln | |
| WO2002060435A1 (fr) | Cryptotanshinone permettant de prevenir et d'attenuer la maladie d'alzheimer | |
| CN101544624A (zh) | 5-羟甲基糠醛缩-5-糠醛甲醇及其制备方法及其医药用途 | |
| JPS6033424B2 (ja) | フェニルエチルアミンの誘導体、その製造方法およびフェニルエチルアミンの誘導体を有効成分とする高血圧および心臓血管病の治療薬 | |
| US4540709A (en) | Method for treatment of diseases mediated by PAF using 5-allyl-2-(3,4-Dimethoxyphenyl)-3a,α-methoxy-3-methyl-2,3,3a,6-tetrahydro-6-oxobenzofuran | |
| CN101085793A (zh) | 一类具有镇静活性的含1,3,4－噁二唑杂环的豆腐果甙新药及其制备方法 | |
| JP2754644B2 (ja) | 新規リグナン類およびリグナン類を有効成分とする５―リポキシゲナーゼ阻害剤およびアルドースリダクターゼ阻害剤 | |
| CN115043814B (zh) | 一种用于治疗心肌缺血的药物及其应用 | |
| KR100516647B1 (ko) | 당뇨병 치료제 조성물 | |
| JPS6299324A (ja) | 脳循環代謝改善剤 | |
| CN111909007A (zh) | 对羟基苯基丁二醇和其衍生物及其制备方法与应用 | |
| JP2756941B2 (ja) | ２−クロロ−３−アリールアミノ−１，４−ナフトキノン誘導体の血小板凝集抑制剤としての用途 | |
| JPH01221321A (ja) | 脂質過酸化抑制剤 | |
| KR100516648B1 (ko) | 리그난 화합물 및 이 물질을 유효성분으로 함유하는 당뇨병 치료제 | |
| JPS609023B2 (ja) | インジルビン誘導体およびそれを含有する抗腫瘍剤 |